Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced the dosing of the first batch of patients in two Phase I clinical studies for its investigational drug ASC30 in the United States. ASC30 is positioned as the world’s first and only small molecule glucagon-like peptide-1 receptor (GLP-1 R) agonist, offering a potential treatment for obesity with a unique dosing regimen. The drug can be administered subcutaneously once a month or orally on a daily basis.
The tablets and injection forms of ASC30 received clearance for clinical trials in the U.S. in July and September of this year, respectively. The company anticipates the release of topline results from these two studies during the first quarter of 2025, marking a significant milestone in the development of this innovative obesity treatment. – Flcube.com
